ClinicalTrials.gg
Not yet recruitingNCT07845201Updated Sep 30, 2026

Intermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy

An observational study in Heart Failure With Reduced Ejection Fraction and HFrEF - Heart Failure With Reduced Ejection Fraction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Assiut University · Observational

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Heart Failure by Assiut University — 12 open to participants now, 12 under way, none of them phase 3. Heart Failure · Assiut University.

Planned enrollment
4th of 20
250 · median 100
Started
2026
with 4 others
Observational
20 of 23
11 open now
Primary completion
2027-09
later than 7 of 11 live
Registered
22nd of 23
by date

Among the 23 studies in Heart Failure by Assiut University, this one is the 4th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 22nd registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

12 of the 23 studies in Heart Failure by Assiut University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Heart Failure by Assiut University, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy over a 6 to 12 month follow-up period.

Read the detailed description

Guideline-directed medical therapy (GDMT) is the cornerstone of treatment for heart failure with reduced ejection fraction. This observational study will enroll adult patients with chronic HFrEF (LVEF ≤ 40%) who are stable on or planned to initiate GDMT.

Patients will be followed for 6 to 12 months to assess changes in renal function, functional status, quality of life, left ventricular ejection fraction, hospitalization rates, and medication adherence.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction
  • HFrEF - Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • Guideline-directed medical therapy
  • GDMT
  • HFrEF
  • Assiut
  • Heart failure outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with chronic heart failure with reduced ejection fraction attending the Cardiovascular Department at Assiut University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of chronic HFrEF with ≤ 40% documented by echocardiography
  • Stable on or planned initiation of guideline-directed medical therapy
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • - Acute decompensated heart failure requiring intravenous inotropes at enrollment
  • End-stage renal disease on dialysis
  • less than 20 mL/min/1.73 m² at baseline
  • Severe primary valvular disease requiring immediate intervention
  • less than 6 months due to non-cardiac illness
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: HFrEF patients on GDMT

    Adult patients with heart failure with reduced ejection fraction who are receiving or planned to receive contemporary guideline-directed medical therapy and will be followed for intermediate outcomes.

06

What researchers measure

Primary outcomes

  1. Change in NYHA functional class

    Change in New York Heart Association (NYHA) functional class from baseline to follow-up.

    Time frame: Baseline and at 6 to 12 months

Secondary outcomes

  1. Change in KCCQ-12 score

    Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) total score from baseline to follow-up (range 0-100, higher scores indicate better health status).

    Time frame: From baseline to 6 to 12 months

  2. Change in left ventricular ejection fraction

    Change in left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to follow-up.

    Time frame: From baseline to 6 to 12 months

  3. Change in estimated glomerular filtration rate

    Change in estimated glomerular filtration rate (eGFR) calculated by CKD-EPI equation from baseline to follow-up.

    Time frame: From baseline to 6 to 12 months

  4. Rate of heart failure hospitalization

    Number of heart failure-related hospital admissions during the follow-up period.

    Time frame: From baseline to 6 to 12 months

  5. Proportion of patients on each GDMT component

    Proportion of patients prescribed each of the four foundational GDMT drug classes at follow-up.

    Time frame: At 6 to 12 months

  6. Medication adherence score

    Mean Morisky Medication Adherence Scale-8 (MMAS-8) score (range 0-8, higher scores indicate better adherence).

    Time frame: At 6 to 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 794 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 12 months is below that.

Counting every sponsor, half of 976 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Feb 20, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionChange in KCCQ-12 score: how it is measured was reworded
  • DescriptionMedication adherence score: how it is measured was reworded
Sep 30, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Sep 30, 2026
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChange in KCCQ-12 score: how it is measured was reworded
    • DescriptionMedication adherence score: how it is measured was reworded
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845201
Lead sponsor
Assiut University
Responsible party
Karim Atef Ali Ahmed (Resident Physician, Department of Cardiovascular medicine, Assiut University) — Principal investigator
First posted
Sep 28, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Karim A Ali, Resident
Contact
kbs621304@gmail.com
+20 10 69625533
Ayman k Mohammed, prof
study chair · Cardiovascular Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion